Cargando…

Potent and Persistent Antibody Response in COVID-19 Recovered Patients

SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Virus-specific antibodies can be detected in infected patients approximately two weeks after symptom onset. In this study, we set up ELISA technology coating with purified SARS-CoV-2 S and N proteins to study the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Xiaodong, Liu, Ling, Jiang, Wenguo, Zhang, He, Liu, Wenjun, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193946/
https://www.ncbi.nlm.nih.gov/pubmed/34122416
http://dx.doi.org/10.3389/fimmu.2021.659041
_version_ 1783706324734836736
author Tian, Xiaodong
Liu, Ling
Jiang, Wenguo
Zhang, He
Liu, Wenjun
Li, Jing
author_facet Tian, Xiaodong
Liu, Ling
Jiang, Wenguo
Zhang, He
Liu, Wenjun
Li, Jing
author_sort Tian, Xiaodong
collection PubMed
description SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Virus-specific antibodies can be detected in infected patients approximately two weeks after symptom onset. In this study, we set up ELISA technology coating with purified SARS-CoV-2 S and N proteins to study the antibody response of 484 serum samples. We established a surrogate viral inhibition assay using SARS-CoV-2 S protein pseudovirus system to determine the neutralization potency of collected serum samples. Here, we report robust antibody responses to SARS-CoV-2 in 484 recovered patients varying from 154 to 193 days, with 92% of recovered patients displaying a positive virus-specific spike glycoprotein IgG (s-IgG) response, while the ratio of positive spike glycoprotein IgM (s-IgM) reached 63%. Furthermore, moderate to potent neutralization activities were also observed in 62% of patients, correlating significantly with s-IgG response. This study strongly supports the long-term presence of antibodies in recovered patients against SARS-CoV-2, although all serum samples were collected from individuals with mild or moderate symptoms.
format Online
Article
Text
id pubmed-8193946
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81939462021-06-12 Potent and Persistent Antibody Response in COVID-19 Recovered Patients Tian, Xiaodong Liu, Ling Jiang, Wenguo Zhang, He Liu, Wenjun Li, Jing Front Immunol Immunology SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Virus-specific antibodies can be detected in infected patients approximately two weeks after symptom onset. In this study, we set up ELISA technology coating with purified SARS-CoV-2 S and N proteins to study the antibody response of 484 serum samples. We established a surrogate viral inhibition assay using SARS-CoV-2 S protein pseudovirus system to determine the neutralization potency of collected serum samples. Here, we report robust antibody responses to SARS-CoV-2 in 484 recovered patients varying from 154 to 193 days, with 92% of recovered patients displaying a positive virus-specific spike glycoprotein IgG (s-IgG) response, while the ratio of positive spike glycoprotein IgM (s-IgM) reached 63%. Furthermore, moderate to potent neutralization activities were also observed in 62% of patients, correlating significantly with s-IgG response. This study strongly supports the long-term presence of antibodies in recovered patients against SARS-CoV-2, although all serum samples were collected from individuals with mild or moderate symptoms. Frontiers Media S.A. 2021-05-28 /pmc/articles/PMC8193946/ /pubmed/34122416 http://dx.doi.org/10.3389/fimmu.2021.659041 Text en Copyright © 2021 Tian, Liu, Jiang, Zhang, Liu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tian, Xiaodong
Liu, Ling
Jiang, Wenguo
Zhang, He
Liu, Wenjun
Li, Jing
Potent and Persistent Antibody Response in COVID-19 Recovered Patients
title Potent and Persistent Antibody Response in COVID-19 Recovered Patients
title_full Potent and Persistent Antibody Response in COVID-19 Recovered Patients
title_fullStr Potent and Persistent Antibody Response in COVID-19 Recovered Patients
title_full_unstemmed Potent and Persistent Antibody Response in COVID-19 Recovered Patients
title_short Potent and Persistent Antibody Response in COVID-19 Recovered Patients
title_sort potent and persistent antibody response in covid-19 recovered patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193946/
https://www.ncbi.nlm.nih.gov/pubmed/34122416
http://dx.doi.org/10.3389/fimmu.2021.659041
work_keys_str_mv AT tianxiaodong potentandpersistentantibodyresponseincovid19recoveredpatients
AT liuling potentandpersistentantibodyresponseincovid19recoveredpatients
AT jiangwenguo potentandpersistentantibodyresponseincovid19recoveredpatients
AT zhanghe potentandpersistentantibodyresponseincovid19recoveredpatients
AT liuwenjun potentandpersistentantibodyresponseincovid19recoveredpatients
AT lijing potentandpersistentantibodyresponseincovid19recoveredpatients